Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1 (GLP-1).
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| GUTS | FRACTYL HEALTH, INC. | 2025-10-30 18:58:22 | 1.25 | 0.02 | 1.47 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GUTS | 0001572616 | FRACTYL HEALTH, INC. | US35168W1036 | — | 273553477 | Nasdaq | 3841 | Surgical & Medical Instruments & Apparatus | 1231 | DE | 3 VAN DE GRAAFF DRIVE | BURLINGTON | MA | 01803 | UNITED STATES | US | 781-902-8800 | 3 VAN DE GRAAFF DRIVE, BURLINGTON, MA, 01803 | 3 VAN DE GRAAFF DRIVE, BURLINGTON, MA, 01803 | Fractyl Laboratories Inc. | Metabolic diseases | 2010 | Harith Rajagopalan | 88 | http://fractyl.com | 144,400,000 | 49,917,791 | 50,289,014 | Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1 (GLP-1). | 2025-10-30 16:25:56 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 144,400,000 | 144,400,000 | 100 | 48,920,221 | 48,920,221 | 100 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Harith Rajagopalan | Chief Executive Officer | 2024 | 604,462 | — | 0 | 274,500 | 600 | 4,856,361 |
| Jay D. Caplan | President, Chief Product Officer | 2024 | 468,077 | — | 0 | 142,500 | 600 | 2,198,612 |
| Lisa A. Davidson | Chief Financial Officer, Treasurer | 2024 | 445,385 | — | 0 | 135,000 | 600 | 1,972,272 |
| Harith Rajagopalan | Chief Executive Officer | 2023 | 550,000 | — | 2,430,014 | 313,500 | 270 | 3,561,774 |
| Jay D. Caplan | President, Chief Product Officer | 2023 | 400,000 | — | 2,097,678 | 154,000 | 1,188 | 2,873,373 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 107 |
| 2023 | 102 |
| Fiscal Year | 2024 |
|---|---|
| Revenue | 93,000 |
| Cost Of Revenue | 50,000 |
| Gross Profit | 43,000 |
| Research And Development Expenses | 70,471,000 |
| General And Administrative Expenses | 23,103,000 |
| Operating Expenses | 93,574,000 |
| Operating Income | -93,531,000 |
| Net Income | -68,694,000 |
| Earnings Per Share Basic | -1.62 |
| Earnings Per Share Diluted | -1.62 |
| Weighted Average Shares Outstanding Basic | 43,541,527 |
| Weighted Average Shares Outstanding Diluted | 43,541,527 |
| Fiscal Year | 2024 |
|---|---|
| Cash And Cash Equivalents | 67,464,000 |
| Marketable Securities Current | — |
| Accounts Receivable | 0 |
| Inventories | 73,000 |
| Non Trade Receivables | — |
| Other Assets Current | — |
| Total Assets Current | 71,763,000 |
| Marketable Securities Non Current | — |
| Property Plant And Equipment | 2,979,000 |
| Other Assets Non Current | 666,000 |
| Total Assets Non Current | 36,314,000 |
| Total Assets | 108,077,000 |
| Accounts Payable | 3,240,000 |
| Deferred Revenue | — |
| Short Term Debt | — |
| Other Liabilities Current | — |
| Total Liabilities Current | 19,775,000 |
| Long Term Debt | 30,162,000 |
| Other Liabilities Non Current | 998,000 |
| Total Liabilities Non Current | 59,878,000 |
| Total Liabilities | 79,653,000 |
| Common Stock | 0 |
| Retained Earnings | -415,310,000 |
| Accumulated Other Comprehensive Income | — |
| Total Shareholders Equity | 28,424,000 |
| Fiscal Year | 2024 |
|---|---|
| Depreciation And Amortization | 677,000 |
| Share Based Compensation Expense | 14,426,000 |
| Other Non Cash Income Expense | — |
| Change In Accounts Receivable | -22,000 |
| Change In Inventories | — |
| Change In Non Trade Receivables | — |
| Change In Other Assets | — |
| Change In Accounts Payable | 2,686,000 |
| Change In Other Liabilities | — |
| Cash From Operating Activities | -65,521,000 |
| Purchases Of Marketable Securities | — |
| Sales Of Marketable Securities | — |
| Acquisition Of Property Plant And Equipment | 1,765,000 |
| Acquisition Of Business | — |
| Other Investing Activities | — |
| Cash From Investing Activities | -1,765,000 |
| Tax Withholding For Share Based Compensation | — |
| Payments Of Dividends | — |
| Issuance Of Common Stock | — |
| Repurchase Of Common Stock | — |
| Issuance Of Long Term Debt | — |
| Repayment Of Long Term Debt | — |
| Other Financing Activities | — |
| Cash From Financing Activities | 101,226,000 |
| Change In Cash | 33,940,000 |
| Cash At End Of Period | 67,464,000 |
| Income Taxes Paid | — |
| Interest Paid | 3,127,000 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Sheffield Ian | Director | 2025-09-02 | 45,000 | A | 45,000 |
| Thompson Christopher Charles | Director | 2025-09-02 | 45,000 | A | 45,000 |
| Conaway Samuel | Director | 2025-06-11 | 22,500 | A | 22,500 |
| Royan Ajay | Director, 10% owner | 2025-06-11 | 22,500 | A | 22,500 |
| Barnes Kelly Ann | Director | 2025-06-11 | 22,500 | A | 22,500 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Parkside Financial Bank & Trust | 2025-09-30 | 25,924 | 16,304 | 1.59 |
| Chicago Partners Investment Group LLC | 2025-09-30 | 39,680 | 31,000 | 1.28 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 2025-09-30 | 1,472,100 | 925,849 | 1.59 |
| St. Johns Investment Management Company, LLC | 2025-09-30 | 3,148 | 1,980 | 1.5899 |
| Cerity Partners LLC | 2025-09-30 | 21,570 | 13,566 | 1.59 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Series Total Market Index Fund | FCFMX | 10,987 | 10,670.57 | 0.0 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Total Market Index Fund | FSKAX | 14,685 | 14,262.07 | 0.0 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Nasdaq Composite Index Fund | FNCMX | 29,844 | 28,984.49 | 0.0001 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Extended Market Index Fund | FSMAX | 40,829 | 39,653.12 | 0.0001 |
| MFS SERIES TRUST I | 2025-08-31 | R6 | MNDKX | 639,147 | 620,739.57 | 0.0298 |